Clinical trials: Chronic and Episodic Headache
Cluster Headache - Episodic and Chronic
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.
- Trial name
- NCT02619617
- Testing
- SOM230
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Migraine Disorders
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Chronic Migraine (CM), or 15 or more migraine headaches per month, is common in tertiary headache care and is associated with a number of deleterious outcomes, especially higher disability and poorer quality of life, relative to…
- Trial name
- NCT01435941
- Testing
- Non-steroidal anti-inflammatory drug (NSAID), Triptan
- Volunteers
- 11,249 people
- Sponsor
- GlaxoSmithKline
Migraine
Study of EVO756 in Adults With Migraine
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
- Trial name
- NCT07616128
- Testing
- EVO756, Dose 1, EVO756, Dose 2
- Where
- 35 sites in United States, Canada and 1 more
- Volunteers
- 330 people
- Sponsor
- Evommune, Inc.
Migraine
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these…
- Trial name
- PROCEED (NCT06323928)
- Testing
- Lu AG09222
- Where
- 120 sites in United States, Bulgaria and 12 more
- Volunteers
- 874 people
- Sponsor
- H. Lundbeck A/S
Migraine
Biomarker and Genetic Predictors of Erenumab Treatment Response
To explore the relationship between clinical response to erenumab and genetic biomarkers
- Trial name
- INTERROGATE (NCT04265755)
- Testing
- Erenumab
- Where
- 2 sites in Denmark, Iceland
- Volunteers
- 1,406 people
- Sponsor
- Amgen
Migraine
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
- Trial name
- REJOIN (NCT05164172)
- Testing
- Eptinezumab
- Where
- 64 sites in United States, Argentina and 9 more
- Volunteers
- 600 people
- Sponsor
- H. Lundbeck A/S
Chronic Migraine, Episodic Migraine
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Conditions
- Chronic Migraine, Episodic Migraine, Migraine
- Trial name
- Atogepant PMSS (NCT06603558)
- Testing
- Atogepant
- Where
- 36 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- AbbVie
Migraine
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment…
- Trial name
- NCT04530110
- Testing
- Fremanezumab
- Where
- 70 sites in United States, Canada and 7 more
- Volunteers
- 499 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Migraine
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
A migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- ATO-TOPIRAMATE (NCT05748483)
- Testing
- Atogepant, Topiramate
- Where
- 81 sites in Austria, Belgium and 10 more
- Volunteers
- 545 people
- Sponsor
- AbbVie
Chronic Migraine or Episodic Migraine
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
To evaluate the effect of AMG 301 compared to placebo on the change from the baseline period in monthly migraine days in subjects with migraine.
- Trial name
- NCT03238781
- Testing
- AMG 301
- Where
- 49 sites in United States, Austria and 6 more
- Volunteers
- 343 people
- Sponsor
- Amgen
Migraine
Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- PRACTICE (NCT07690215)
- Volunteers
- 200 people
- Sponsor
- AbbVie
Cluster Headache
Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches
This is a double-blind, placebo-controlled study. Subjects who meet the entry criteria will be randomized o receive one of three blinded treatments [C213 1.9 mg patch and placebo patch; C213 3.8 mg (1.9 mg x 2 patches), two…
- Trial name
- NCT04066023
- Testing
- C213 Microneedle System
- Where
- 12 sites in United States
- Volunteers
- 42 people
- Sponsor
- Zosano Pharma Corporation
Episodic Cluster Headache, Chronic Cluster Headache
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL…
- Trial name
- NCT02797951
- Testing
- Galcanezumab
- Where
- 40 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Eli Lilly and Company
Cluster Headache
A Randomized Multicentre Study for the Acute Relief of Episodic and Chronic Cluster Headache.
The study will look at a non-invasive treatment for people suffering with chronic and episodic headaches. Study subjects will be randomized to an active treatment or an in-active treatment for 2 weeks.
- Trial name
- NCT01958125
- Testing
- gammaCore
- Where
- 9 sites in Denmark, Germany and 2 more
- Volunteers
- 102 people
- Sponsor
- ElectroCore INC
Migraine
Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Preventative Treatment for Migraine
This is a prospective, randomized, open-label, delayed-start clinical investigation evaluating the safety and efficacy of the Walther System, a Class IIa investigational medical device delivering intra-nasal mechanical…
- Trial name
- A-MI-01 (NCT07279623)
- Testing
- INMEST-treatment
- Where
- Sweden
- Volunteers
- 110 people
- Sponsor
- Abilion Medical Systems AB
Migraine
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could…
- Trial name
- HER-MES (NCT03828539)
- Testing
- Erenumab, Topiramate
- Where
- 79 sites in Germany
- Volunteers
- 777 people
- Sponsor
- Novartis Pharmaceuticals
Migraine, Migraine Disorders
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.
- Conditions
- Migraine, Migraine Disorders, Migraine Headache
- Trial name
- APOLLON (NCT04084314)
- Testing
- Erenumab
- Where
- 75 sites in Germany
- Volunteers
- 701 people
- Sponsor
- Novartis Pharmaceuticals
Resistant Migraine, Chronic Migraine Headache
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
The purpose of this pivotal clinical study is to evaluate the safety and effectiveness of the MySalvia System, a minimally invasive implantable neuromodulation therapy, for the preventive treatment of adults with resistant…
- Conditions
- Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
- Trial name
- RECLAIM-II (NCT07719608)
- Testing
- Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Salvia BioElectronics
Migraine Disorders
Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines
The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.
- Trial name
- NCT03716505
- Testing
- gammaCore Sapphire active
- Where
- 30 sites in United States
- Volunteers
- 231 people
- Sponsor
- ElectroCore INC
Migraine
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
Migraine is a very common, neurological disorder, characterized by recurrent episodes of headache, potential progression to more frequent and severe attack patterns, and associated symptoms.
- Trial name
- COMIG (NCT04114630)
- Testing
- erenumab 70mg/mL
- Where
- 27 sites in Spain
- Sponsor
- Novartis Pharmaceuticals